ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 278 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,931,205 | -15.9% | 369,602 | +11.7% | 0.00% | -25.0% |
| Q2 2023 | $11,802,390 | +55.2% | 330,970 | +10.6% | 0.00% | +33.3% |
| Q1 2023 | $7,603,286 | -39.1% | 299,342 | -2.7% | 0.00% | -40.0% |
| Q4 2022 | $12,480,717 | +264.7% | 307,710 | +197.2% | 0.01% | +150.0% |
| Q3 2022 | $3,422,000 | +6.5% | 103,546 | +13.5% | 0.00% | +100.0% |
| Q2 2022 | $3,212,000 | -56.2% | 91,217 | -42.7% | 0.00% | -50.0% |
| Q1 2022 | $7,328,000 | -28.7% | 159,326 | +2.8% | 0.00% | -33.3% |
| Q4 2021 | $10,278,000 | +26.6% | 155,016 | +19.2% | 0.00% | 0.0% |
| Q3 2021 | $8,116,000 | +35.7% | 130,000 | +80.0% | 0.00% | +50.0% |
| Q2 2021 | $5,981,000 | +25.4% | 72,213 | +0.4% | 0.00% | 0.0% |
| Q1 2021 | $4,771,000 | +437.9% | 71,941 | +522.6% | 0.00% | – |
| Q4 2020 | $887,000 | -37.8% | 11,555 | -65.1% | 0.00% | -100.0% |
| Q3 2020 | $1,427,000 | +323.4% | 33,138 | +324.6% | 0.00% | – |
| Q2 2020 | $337,000 | -2.9% | 7,804 | -35.3% | 0.00% | – |
| Q1 2020 | $347,000 | -97.4% | 12,053 | -94.2% | 0.00% | -100.0% |
| Q4 2019 | $13,204,000 | +121.6% | 208,175 | -1.5% | 0.01% | +150.0% |
| Q3 2019 | $5,958,000 | +96.5% | 211,411 | +84.8% | 0.00% | +100.0% |
| Q2 2019 | $3,032,000 | +202.6% | 114,426 | +109.5% | 0.00% | – |
| Q1 2019 | $1,002,000 | -71.1% | 54,614 | -80.4% | 0.00% | -100.0% |
| Q4 2018 | $3,465,000 | +116.3% | 279,019 | +233.8% | 0.00% | +100.0% |
| Q3 2018 | $1,602,000 | +255.2% | 83,583 | +152.2% | 0.00% | – |
| Q2 2018 | $451,000 | -69.2% | 33,140 | -83.7% | 0.00% | -100.0% |
| Q1 2018 | $1,462,000 | +1661.4% | 202,765 | +798.0% | 0.00% | – |
| Q4 2017 | $83,000 | +62.7% | 22,579 | +89.8% | 0.00% | – |
| Q3 2017 | $51,000 | +410.0% | 11,898 | +110.3% | 0.00% | – |
| Q2 2017 | $10,000 | 0.0% | 5,657 | +6.7% | 0.00% | – |
| Q1 2017 | $10,000 | -56.5% | 5,300 | -63.9% | 0.00% | – |
| Q4 2016 | $23,000 | -85.1% | 14,680 | -30.0% | 0.00% | – |
| Q3 2016 | $154,000 | +242.2% | 20,960 | +145.1% | 0.00% | – |
| Q2 2016 | $45,000 | – | 8,550 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,264 | $54,392,000 | 33.22% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $216,228,000 | 28.00% |
| L1 Capital Pty Ltd | 296,024 | $19,629,000 | 4.93% |
| Aquilo Capital Management, LLC | 407,926 | $27,050,000 | 4.89% |
| Evolutionary Tree Capital Management, LLC | 72,948 | $4,837,000 | 2.86% |
| ACUTA CAPITAL PARTNERS, LLC | 108,000 | $7,161,000 | 2.58% |
| First Light Asset Management, LLC | 536,836 | $35,598,000 | 2.36% |
| Parkman Healthcare Partners LLC | 70,089 | $4,648,000 | 1.08% |
| Hood River Capital Management LLC | 357,082 | $23,678,000 | 0.76% |
| Vanguard Capital Wealth Advisors | 11,099 | $703,565,000 | 0.60% |